epirubicin
Showing 1 - 25 of 173
Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)
Completed
- Breast Neoplasms
- Epirubicin
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Oct 26, 2022
Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Docetaxel
- +3 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023
Soft Tissue Sarcoma Trial in Beijing, Shanghai (Anlotinib HCl capsule, Epirubicin, Arotinib HCl capsule )
Recruiting
- Soft Tissue Sarcoma
- Anlotinib hydrochloride capsule
- +2 more
-
Beijing, Beijing, China
- +2 more
Feb 16, 2022
Sepsis Trial in Germany (Epirubicin, Placebo)
Not yet recruiting
- Sepsis
- Epirubicin
- Placebo
-
Jena, Thuringia, Germany
- +4 more
Feb 25, 2022
Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial (Toripalimab, Epirubicin, High Intensity Focused Ultrasoun)
Not yet recruiting
- Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Toripalimab
- +5 more
- (no location specified)
Aug 5, 2022
Hepatocellular Carcinoma Trial in Hangzhou (Idarubicin Hydrochloride for Injection, Epirubicin)
Not yet recruiting
- Hepatocellular Carcinoma
- Idarubicin Hydrochloride for Injection
- Epirubicin
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 13, 2021
Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)
Not yet recruiting
- Breast Neoplasms
- Trilaciclib
- +7 more
-
Guangzhou, Gangdong, ChinaSun-yat sen university cancer center
Jul 30, 2023
Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)
Recruiting
- Breast Cancer
- Docetaxel
- +6 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022
Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)
Recruiting
- Breast Cancer
- Docetaxel
- +6 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022
Breast Tumors Trial in Saint Louis (Doxorubicin, Trastuzumab, Cyclophosphamide)
Terminated
- Breast Neoplasms
- Doxorubicin
- +7 more
-
Saint Louis, MissouriWashington University School of Medicine
Oct 31, 2022
Bladder Cancer, Non-muscle Invasive Trial in Biel (Epirubicin, Mitomycin, Gemcitabine)
Recruiting
- Bladder Cancer
- Non-muscle Invasive
- Epirubicin
- +3 more
-
Biel, SwitzerlandRoland Seiler
Nov 17, 2022
Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib
- +5 more
-
Shenyang, Liaoning, ChinaXing Xiaojing
Jun 1, 2023
Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)
Completed
- Breast Cancer
- Panitumumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 20, 2022
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Breast Cancer, Neoadjuvant Therapy Trial in Beijing (Utidelone, Carboplatin, Epirubicin)
Not yet recruiting
- Breast Cancer
- Neoadjuvant Therapy
- Utidelone
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Aug 1, 2023
Breast Tumors Trial in Guangzhou (procedure, drug, biological)
Recruiting
- Breast Neoplasms
- Sentinel Lymph Node Biopsy (SLNB)
- +7 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023
Hepatocellular Carcinoma Trial in Nanjing (cTACE, Dicycloplatin (TP21), Epirubicin)
Recruiting
- Hepatocellular Carcinoma
- cTACE
- +2 more
-
Nanjing, Jiangsu, ChinaZhongda Hospital, Southeast University
Jul 22, 2022
HER2-negative Breast Cancer, Neoadjuvant Chemo Trial in Hangzhou (Epirubicin, Cyclophosphamid, Docetaxel)
Recruiting
- HER2-negative Breast Cancer
- Neoadjuvant Chemotherapy
- Epirubicin
- +3 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 9, 2021
Breast Tumors Trial in Guangzhou (procedure, drug, biological)
Recruiting
- Breast Neoplasms
- Sentinel Lymph Node Biopsy (SLNB)
- +7 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2023
Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)
Active, not recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Ruijin Hospital
Dec 1, 2022
Marginal Zone Lymphoma Trial in Zhengzhou (Bortezomib, Rituximab, Epirubicin)
Recruiting
- Marginal Zone Lymphoma
- Bortezomib
- +4 more
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Aug 15, 2021
HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)
Recruiting
- HER2 Positive Early Breast Cancer
- Docetaxel
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023